Skip to main content

Advertisement

SpringerLink
Log in

Mechanisms of differential immunogenicity of tumor necrosis factor inhibitors

  • Invited Commentary
  • Published:
Current Rheumatology Reports Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. American College of Rheumatology Ad Hoc Committee on Clinical Guidelines: Guidelines for the management of rheumatoid arthritis. Arthritis Rheum 1996, 39:713–722.

    Article  Google Scholar 

  2. American College of Rheumatology Subcommittee on Rheumatoid Arthritis Guidelines: Guidelines for the management of rheumatoid arthritis, 2002 update. Arthritis Rheum 2002, 46:328–346.

    Article  Google Scholar 

  3. Costello JC, Halverson PB: A new era in rheumatoid arthritis treatment. WMJ 2003, 102:29–33.

    PubMed  Google Scholar 

  4. Arend WP, Dayer J-M: Cytokines and cytokine inhibitors or antagonists in rheumatoid arthritis. Arthritis Rheum 1990, 33:305–315.

    Article  PubMed  CAS  Google Scholar 

  5. Wooley PH, Dutcher J, Widmer MB, Gillis S: Influence of a recombinant human soluble tumor necrosis factor receptor Fc fusion protein in type II collagen-induced arthritis in mice. J Immunol 1993, 151:6602–6607.

    PubMed  CAS  Google Scholar 

  6. Maini RN, Elliott MJ, Brennan FM, Feldmann M: Beneficial effects of tumour necrosis factor-alpha (TNF-alpha) blockade in rheumatoid arthritis (RA). Clin Exp Immunol 1995, 101:207–212.

    PubMed  CAS  Google Scholar 

  7. Lipsky PE, van der Heijde D, St. Clair W, et al.: Infliximab and methotrexate in the treatment of rheumatoid arthritis. N Engl J Med 2000, 343:1594–1602.

    Article  PubMed  CAS  Google Scholar 

  8. Maini RN, Breedveld FC, Kalden JR, et al.: Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum 1998, 41:1552–1563.

    Article  PubMed  CAS  Google Scholar 

  9. Moreland LW, Schiff MH, Baumgartner SW, et al.: Etanercept therapy in rheumatoid arthritis. Ann Intern Med 1999, 130:478–486.

    PubMed  CAS  Google Scholar 

  10. Weinblatt ME, Kremer JM, Bankhurst AD, et al.: A trial of etanercept, a recombinant tumor necrosis factor receptor: Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 1999, 340:253–259.

    Article  PubMed  CAS  Google Scholar 

  11. Weinblatt ME, Keystone EC, Furst DE, et al.: Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum 2003, 48:35–45.

    Article  PubMed  CAS  Google Scholar 

  12. Louie SG, Park B, Yoon H: Biological response modifiers in the management of rheumatoid arthritis. Am J Health Syst Pharm 2003, 60:346–355.

    PubMed  CAS  Google Scholar 

  13. Drugs for rheumatoid arthritis. Treatment Guidelines from The Medical Letter 2003, 1:25-32.

  14. Jobanputra P, Barton P, Bryan S, Fry-Smith A: The clinical effectiveness and cost-effectiveness of new drug treatments for rheumatoid arthritis: etanercept and infliximab. National Institute for Clinical Excellence Technical Assessment Report. http:// www.nice.org.uk/pdf/RAAssessmentReport.pdf. September 2001.

  15. Hochberg MC, Tracy JK, Hawkins-Holt M, Flores RH: Comparison of the efficacy of the tumour necrosis factor alpha blocking agents adalimumab, etanercept, and infliximab when added to methotrexate in patients with active rheumatoid arthritis. Ann Rheum Dis 2003, 62(Suppl 2):13–6.

    Google Scholar 

  16. Scallon B, Cai A, Solowski N, et al.: Binding and functional comparisons of two types of tumor necrosis factor antagonists. J Pharmacol Exp Ther 2002, 301:418–426.

    Article  PubMed  CAS  Google Scholar 

  17. Scallon BJ, Moore MA, Trinh H, et al.: Chimeric anti-TNF-alpha monoclonal antibody cA2 binds recombinant transmembrane TNF-alpha and activates immune effector functions. Cytokine 1995, 7:251–259.

    Article  PubMed  CAS  Google Scholar 

  18. Lorenz HM, Antoni C, Valerius T, et al.: In vivo blockade of TNF-alpha by intravenous infusion of a chimeric monoclonal TNF-alpha antibody in patients with rheumatoid arthritis. Short term cellular and molecular effects. J Immunol 1996, 156:1646–1653.

    PubMed  CAS  Google Scholar 

  19. van den Brande JM, Braat H, van den Brink GR, et al.: Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn’s disease. Gastroenterology 2003, 124:1774–1785.

    Article  PubMed  Google Scholar 

  20. Di Sabatino A, Ciccocioppo R, Cinque B, et al.: Defective mucosal T cell death is sustainably reverted by infliximab in a caspase dependent pathway in Crohn’s disease. Gut 2004, 53:70–77.

    Article  Google Scholar 

  21. Lugering A, Schmidt M, Lugering N, et al.: Infliximab induces apoptosis in monocytes from patients with chronic active Crohn’s disease by using a caspase-dependent pathway. Gastroenterology 2001, 121:1145–1157.

    Article  PubMed  CAS  Google Scholar 

  22. Infliximab® Prescribing Information [package insert]. Malvern, PA: Centocor Inc.; 2003. Accessed March 4, 2004. http://www.remicade-ra.com/d_for_healthcarepros/d1.jsp#.

  23. Humira™ Prescribing Information [package insert]. Abbott Park, IL: Abbott Laboratories; 2003.

  24. Christen U, Thuerkauf R, Stevens R, Lesslauer W: Immune response to a recombinant human TNFR55-IgG1 fusion protein: auto-antibodies in rheumatoid arthritis (RA) and multiple sclerosis (MS) patients have neither neutralizing nor agonist activities. Hum Immunol 1999, 60:774–790.

    Article  PubMed  CAS  Google Scholar 

  25. Baert F, Noman M, Vermeire S, et al.: Influence of immunogenicity on the long-term efficacy of infliximab in Crohn’s disease. N Engl J Med 2003, 348:601–608.

    Article  PubMed  CAS  Google Scholar 

  26. Zijlstra A, Testa JE, Quigley JP: Targeting the proteome/ epitome, implementation of subtractive immunization. Biochem Biophys Res Commun 2003, 303:733–744.

    Article  PubMed  CAS  Google Scholar 

  27. Geborek P, Crnkic M, Petersson IF, et al.: Etanercept, infliximab, and leflunomide in established rheumatoid arthritis: clinical experience using a structured follow-up programme in southern Sweden. Ann Rheum Dis 2002, 61:793–798.

    Article  PubMed  CAS  Google Scholar 

  28. George D, Kadlubek P, Batra D, Goldberg G: Infliximab dose and charge escalation patterns in managed care. Manag Care Interface 2004, Suppl A:5–11.

    PubMed  Google Scholar 

  29. Kress S: Adalimumab for use in the treatment of rheumatoid arthritis: clinical review. Abbott Laboratories Biologic Licensing Application, 1–136. 12/24/02. Office of Therapeutics Research and Review, Division of Clinical Trial Design and Analysis, Immunology Infection Diseases Branch.

  30. Foerder C, Rogge M: Immunogenicity of Enbrel® (etanercept): clinical trial observations [abstract THU0032]. Paper presented at the Annual European Congress of Rheumatology. Stockholm, Sweden; June 12–15, 2002.

  31. Foerder C, Rogge M: Immunogenicity of Enbrel® (etanercept): clinical trial observations. Poster. Paper presented at the Annual European Congress of Rheumatology. Stockholm, Sweden; June 12–15, 2002.

Download references

Author information

Authors and Affiliations

  1. Brigham and Women’s Hospital, 75 Francis Street, 02115, Boston, MA, USA

    Paul Anderson MD, PhD

Authors
  1. Paul Anderson MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. James Louie MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Anna Lau PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Michael Broder MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Anderson, P., Louie, J., Lau, A. et al. Mechanisms of differential immunogenicity of tumor necrosis factor inhibitors. Curr Rheumatol Rep 7, 3–9 (2005). https://doi.org/10.1007/s11926-005-0002-2

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11926-005-0002-2

Keywords

Search

Navigation